KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Return on Capital Employed (2021 - 2023)

AbCellera Biologics' Return on Capital Employed history spans 3 years, with the latest figure at 0.17% for Q4 2023.

  • For the quarter ending Q4 2023, Return on Capital Employed fell 32.0% year-over-year to 0.17%, compared with a TTM value of 0.17% through Dec 2023, down 32.0%, and an annual FY2024 reading of 0.23%, down 6.0% over the prior year.
  • Return on Capital Employed for Q4 2023 was 0.17% at AbCellera Biologics, down from 0.15% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.32% in Q1 2021, with the low at 0.17% in Q4 2023.
  • Average Return on Capital Employed over 3 years is 0.12%, with a median of 0.19% recorded in 2021.
  • Year-over-year, Return on Capital Employed decreased -3bps in 2022 and then plummeted -38bps in 2023.
  • Tracing ABCL's Return on Capital Employed over 3 years: stood at 0.18% in 2021, then dropped by -17bps to 0.15% in 2022, then tumbled by -213bps to 0.17% in 2023.
  • Per Business Quant, the three most recent readings for ABCL's Return on Capital Employed are 0.17% (Q4 2023), 0.15% (Q3 2023), and 0.08% (Q2 2023).